Table 2.
CLART results for 5,068 samples, by age, screening history, cytology, and HC2 results
| Outcomes on CLART, N (%) | |||||
|---|---|---|---|---|---|
| Any high-risk HPV genotype (%)a | Negative on high-risk HPV genotypes (%)b | Only low-risk HPV genotypes (%)a | Invalid (%) | Total (%) | |
| Total | 1,274 (25.1%) | 3,782 (74.6%) | 622 (12.3%) | 12 (0.2%) | 5,068 (100%) |
| Age (years) | |||||
| 16-22 | 99 (61.1%) | 63 (38.9%) | 20 (12.3%) | 0 (0.0%) | 162 (100%) |
| 23-29 | 608 (39.6%) | 926 (60.3%) | 216 (14.1%) | 1 (0.1%) | 1,535 (100%) |
| 30-39 | 345 (22.6%) | 1,176 (77.1%) | 171 (11.2%) | 4 (0.3%) | 1,525 (100%) |
| 40-49 | 135 (13.6%) | 851 (85.8%) | 119 (12.0%) | 6 (0.6%) | 992 (100%) |
| 50-59 | 54 (10.7%) | 452 (89.2%) | 55 (10.8%) | 1 (0.2%) | 507 (100%) |
| 60-65 | 24 (10.3%) | 210 (89.7%) | 25 (10.7%) | 0 (0.0%) | 234 (100%) |
| >65 | 9 (8.0%) | 104 (92.0%) | 16 (14.2%) | 0 (0.0%) | 113 (100%) |
| Screening history | |||||
| Primary samplec | 1,024 (23.2%) | 3,375 (76.5%) | 528 (12.0%) | 11 (0.2%) | 4,410 (100%) |
| Follow-up sample | 250 (38.0%) | 407 (61.9%) | 94 (14.3%) | 1 (0.2%) | 658 (100%) |
| Cytology | |||||
| Normal | 1,001 (21.4%) | 3,658 (78.3%) | 561 (12.0%) | 12 (0.3%) | 4,671 (100%) |
| ASCUS | 72 (58.5%) | 51 (41.5%) | 18 (14.6%) | 0 (0.0%) | 123 (100%) |
| LSIL | 103 (72.5%) | 39 (27.5%) | 35 (24.6%) | 0 (0.0%) | 142 (100%) |
| ≥HSIL | 97 (91.5%) | 9 (8.5%) | 5 (4.7%) | 0 (0.0%) | 106 (100%) |
| ≥ASCUS | 272 (73.3%) | 99 (26.7%) | 58 (15.6%) | 0 (0.0%) | 371 (100%) |
| Inadequate | 1 (3.8%) | 25 (96.2%) | 3 (11.5%) | 0 (0.0%) | 26 (100%) |
| HC2 d | |||||
| Positive | 874 (84.4%) | 160 (15.5%) | 111 (10.7%) | 1 (0.1%) | 1,035 (100%) |
| Negative | 399 (9.9%) | 3,619 (89.8%) | 510 (12.7%) | 11 (0.3%) | 4,029 (100%) |
Abbreviations: ASCUS atypical squamous cells of undetermined significance, HC2 Hybrid Capture 2 assay, HPV Human Papillomavirus, ≥HSIL high-grade intraepithelial lesions or worse, LSIL low-grade squamous intraepithelial lesions.
aThirteen high-risk and probably high-risk genotypes, according to the classification reported by IARC [2].
bNone of the 13 high-risk or probably high-risk genotypes detected.
cPredominantly screening samples, including a small proportion of samples taken for indication.
dFour samples were not tested with HC2.